Real-World Evidence FDA’s Jacqueline Corrigan-Curay
Executive Summary
In a podcast interview, US FDA Office of Medical Policy Director Jacqueline Corrigan-Curay talks about FDA’s current work on real-world evidence.
You may also be interested in...
Real World Evidence: Between 'Nirvana' And Electronic Roadblocks
US FDA's Jonathan Jarow says it will be up to pharma industry to get right data into electronic health records.
Medicare Proposes Earlier Deadline For Rx Add-On Payment Candidates
Starting in fiscal year 2025, products would need to meet an earlier, May deadline for FDA approval in order to be eligible for enhanced payments in the Hospital Inpatient Prospective Payment System (IPPS). The change would give CMS more to handle the surge in NTAP applications.
Drug Shortages Back In US Congressional Spotlight
Drug shortages were a significant focus of legislative attention in the US before the COVID-19 pandemic, and Congress is not likely to drop the issue now that the public health emergency is winding down.